{
    "abstract": "Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have emerged as a leading pharmacologic for managing weight gain across most populations, including peri and postmenopausal women who frequently suffer from weight gain. There is a paucity of data about this specific population and how they respond to these medications. This review aims to discuss the data available about the use and effects of GLP-1 RAs in the peri and postmenopausal populations.\nGLP-1 RAs are consistently the most effective pharmacologic for weight loss and can be a valuable tool for use in peri and postmenopausal women.\nAdditional research is needed to determine the risks and benefits and ideal use of GLP-1 RAs in peri and postmenopausal women.",
    "authors": [
        {
            "affiliation": "Gennev Medical Group.\nLoma Linda VHA, Loma Linda, California.",
            "firstname": "Hana",
            "initials": "H",
            "lastname": "Mikdachi"
        },
        {
            "affiliation": "Gennev Medical Group.\nSwedish Medical Center.\nWashington State University Elson S Floyd School of Medicine.\nSeattle Clinical Research Center, Seattle, Washinngton, USA.",
            "firstname": "Rebecca",
            "initials": "R",
            "lastname": "Dunsmoor-Su"
        }
    ],
    "conclusions": null,
    "copyrights": "Copyright \u00a9 2025 Wolters Kluwer Health, Inc. All rights reserved.",
    "doi": "10.1097/GCO.0000000000001015",
    "journal": "Current opinion in obstetrics & gynecology",
    "keywords": [],
    "methods": null,
    "publication_date": "2025-02-19",
    "pubmed_id": "39970049",
    "results": null,
    "title": "GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence.",
    "xml": "<Element 'PubmedArticle' at 0x7885062c9990>"
}